KALA PHARMACEUTICALS, INC. KALA Income Statement

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Sep'16	Jun'16
Product revenues, net
5,759	6,074	0	0	0	-	-	-	-	-	-	-	-	-	-
Costs and expenses:
Cost of product revenues
2,121	2,008	0	0	0	-	-	-	-	-	-	-	-	-	-
Selling, general and administrative
62,187	65,015	64,852	58,041	48,185	35,431	0	0	0	-	-	-	-	-	-
Research and development
25,750	27,275	30,375	30,332	30,592	29,290	25,932	25,923	26,626	29,008	0	0	0	0	0
General and administrative
-	-	-	-	-	-	-	-	-	-	0	0	0	0	0
Total costs and expenses
90,058	94,298	96,488	88,966	79,018	64,721	52,294	46,332	41,443	39,875	0	0	0	0	0
Loss from operations
-84,299	-88,224	-91,594	-85,523	-77,632	-64,721	-52,294	-46,332	-41,443	-39,875	0	0	0	0	0
Other income (expense):
Interest income
1,899	2,357	2,813	2,567	2,234	1,687	1,097	966	690	527	0	0	0	0	0
Interest expense
8,514	8,480	8,436	6,688	5,041	3,314	1,614	1,394	1,188	1,019	0	0	0	0	0
Change in fair value of warrant liability
-	-	-	-	-	-	-	-	-	1,844	0	0	0	0	0
Total other expense
-6,615	-6,123	-6,013	-4,511	-3,197	-2,017	-517	-1,051	-2,306	-2,336	0	0	0	0	0
Net loss
-90,914	-94,347	-97,607	-90,034	-80,829	-66,738	-52,811	-47,383	-43,749	-42,211	0	0	0	0	0
Net loss per share—basic and diluted
-0.54	-0.63	-0.68	-0.70	-0.75	-0.80	-0.63	-0.60	-0.46	14.41	-0.56	-9.30	-8.26	-8.18	-8.34
Weighted average shares outstanding—basic and diluted
40,761	34,909	34,168	33,882	33,878	33,306	24,600	24,567	24,542	25,102	18,034	1,181	1,181	1,181	1,181